Item 7.01. Regulation FD Disclosure.
During its annual meeting of stockholders to be held on June 22, 2022, Provectus
Biopharmaceuticals, Inc. (the “Company”) will provide an update about the
Company’s clinical development, regulatory affairs, drug discovery,
manufacturing, intellectual property, business development, and corporate
development activities.
A copy of the Company’s 2022 Annual Meeting of Stockholders presentation slides
is attached to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission,
the information in this Item 7.01 disclosure, including Exhibit 99.1 and
information set forth therein, is deemed to have been furnished and shall not be
deemed to be “filed” under the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 2022 Annual Meeting of Stockholders presentation slides
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses
postbrexitcompliance.com 